June Sherie Almenoff

June Sherie Almenoff (board member) discloses dealings in 7 companies, chiefly Furiex Pharmaceuticals, Inc., 9 Meters Biopharma, Inc. and Brainstorm Cell Therapeutics Inc. In total, 39 filings cover trades dated from 9 September 2011 to 2 September 2026.

In open-market terms, that means 24 purchases worth €264k on one side and 2 sales worth €9.8M on the other. On balance, insiders were net sellers of €9.5M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 6 share grants and 6 option exercises.

In size, the median ticket on the buying side is €6,153. Of 11 purchases, 8 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The record was last updated on 4 September 2026 with a share grant in Actinium Pharmaceuticals, Inc. The last purchase on record was published on 20 November 2025, which is 338 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.